✦ LIBER ✦

Changing practice of elective tracheostomies in head and neck oncology patients at the John Radcliffe Hospital, Oxford

✍ Scribed by P. Kiwanuka; T. Wildan; V. Patel; M. Ruparelia; K. Fasanmade

Book ID: 116318055
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 79 KB
Volume: 49
Category: Article
ISSN: 0266-4356
DOI: 10.1016/j.bjoms.2011.03.256

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

(4) Transoral Robotic Surgery in the Tre

(4) Transoral Robotic Surgery in the Treatment of Head and Neck Cancer Patients: Initial Experience at the Royal Adelaide Hospital

✍ John-Charles Hodge; Suren Krishnan; Guy Rees 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 97 KB

A phase 2 trial of bortezomib followed b

A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck : A trial of the eastern cooperative oncology group (E1303)

✍ Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S. Axelrod; Ron 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Abstract ## BACKGROUND: Bortezomib, an inhibitor of the 26S proteasome and NF‐κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin. ## METHODS: Eligibility criteria included incurable ACC, any number of pr

Detection of lung tumours in patients wi

Detection of lung tumours in patients with squamous cell carcinoma of the head and neck at the time of presentation : Abstracts of the Spring 2008 Meeting of the Otorhinolaryngological Research Society The following are the abstracts of the Spring 2008 Meeting of the Otorhinolaryngological Research Society held on 31st March 2008 at the University Hospital Coventry, Coventry, UK

✍ S. Ghosh; A. Kumar; N. Roland; S. Tandon; J. Lancaster; S. Jackson; A. Jones; H. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Phase II 2-arm trial of the proteasome i

Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group

✍ Jill Gilbert; Ju Whei Lee; Athanassios Argiris; Missak Haigentz Jr.; Lawrence Er 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 776 KB